Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

Vitali, C., Bombardieri, S., Jonsson, R., Moutsopoulos, H. M., Alexander, E. L., Carsons, S. E., Daniels, T. E., Fox, P. C., Fox, R. I., Kassan, S. S., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.6.554 · Cited by 5,285 · see citing works

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623 · see citing works

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene

Cartron, G., Dacheux, L., Salles, G., Solal‐Céligny, P., BARDOS, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,902 · see citing works

Easy SAS Calculations for Risk or Prevalence Ratios and Differences

Spiegelman, D. L. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi188 · Cited by 1,729 · see citing works

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

Rovin, B. H., Furie, R. A., Latinis, K. M., Looney, R. J., Fervenza, F. C., Sánchez‐Guerrero, J., Maciuca, R. D., Zhang, D., Garg, J. P., Brunetta, P. G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,467 · see citing works

Labial salivary gland biopsy in Sjögren's disease

CHISHOLM, D. M., & Mason, D. K. (1968) · Journal of Clinical Pathology · doi:10.1136/jcp.21.5.656 · Cited by 1,018 · see citing works

EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome

Séror, R., Ravaud, P., Bowman, S., Baron, G., Tzioufas, A. G., Theander, E., Gottenberg, J., Bootsma, H., Xavier Mariette, A., & Vitali, C. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.110619 · Cited by 969 · see citing works

BINOMIAL REGRESSION IN GLIM: ESTIMATING RISK RATIOS AND RISK DIFFERENCES1

Wacholder, S. (1986) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a114212 · Cited by 634 · see citing works

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome

Gottenberg, J., Cagnard, N., Lucchesi, C., Letourneur, F., Mistou, S., Lazure, T., Jacques, S., Bâ, N., Ittah, M., Lepajolec, C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510837103 · Cited by 606 · see citing works

Rituximab treatment in patients with primary Sjögren's syndrome: An open‐label phase II study

Pijpe, J., Imhoff, G. W. V., Spijkervet, F. K. L., Roodenburg, J. L. N., Wolbink, G., Mansour, K., Vissink, A., Kallenberg, C. G. M., & Bootsma, H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21260 · Cited by 497 · see citing works

Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial

Meijer, J. M., Meiners, P. M., Vissink, A., Spijkervet, F. K. L., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C. G. M., & Bootsma, H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27314 · Cited by 488 · see citing works

Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS)

Xavier Mariette, A., Ravaud, P., Steinfeld, S. D., Baron, G., Goetz, J., HACHULLA, E., Combe, B. G., Puéchal, X., Pennec, Y. L., Sauvezie, B., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20146 · Cited by 432 · see citing works

Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study

Dass, S. J., Bowman, S., Vital, E. M. J., Ikeda, K., Pease, C. T., Hamburger, J., Richards, A., Rauz, S., & Emery, P. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083865 · Cited by 428 · see citing works

Treatment of Primary Sjögren Syndrome

Ramos‐Casals, M., Tzioufas, A. G., Stone, J. H., Sisó‐Almirall, A., & Bosch, X. (2010) · JAMA · doi:10.1001/jama.2010.1014 · Cited by 375 · see citing works

CD20 deficiency in humans results in impaired T cell–independent antibody responses

Kuijpers, T. W., Bende, R. J., Baars, P. A., Grummels, A., Derks, I. A. M., Dolman, K. M., Beaumont, T., Tedder, T. F., van Noesel, C. J. M., Eldering, E., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40231 · Cited by 374 · see citing works

Improvement of Sjögren's syndrome after two infusions of rituximab (anti‐CD20)

Devauchelle‐Pensec, V., Pennec, Y. L., Morvan, J., Pers, J., Daridon, C., Jousse‐Joulin, S., Roudaut, A., Jamin, C., Renaudineau, Y., Quintin‐Roué, I., et al. (2007) · Arthritis Care & Research · doi:10.1002/art.22536 · Cited by 311 · see citing works

Etanercept in Sjögren's syndrome: A twelve‐week randomized, double‐blind, placebo‐controlled pilot clinical trial

Sankar, V., Brennan, M. T., Kok, M. R., Leakan, R. A., Smith, J. A., Manny, J., Baum, B. J., & Pillemer, S. R. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20299 · Cited by 304 · see citing works

A Novel IL-10-Independent Regulatory Role for B Cells in Suppressing Autoimmunity by Maintenance of Regulatory T Cells via GITRL

Ray, A., Basu, S., Williams, C. B., Salzman, N., & Dittel, B. (2012) · Journal of Immunology · doi:10.4049/jimmunol.1103354 · Cited by 278 · see citing works

Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjogren's syndrome

Jonsson, M. V., Szodoray, P., Jellestad, S., Jonsson, R., & Skarstein, K. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-4091-5 · Cited by 229 · see citing works

BAFF‐modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB‐TREATED patients with Sjögren's syndrome

Pers, J., Devauchelle‐Pensec, V., Daridon, C., Bendaoud, B., Berre, R. L., Bordron, A., Hutin, P., Renaudineau, Y., Dueymes, M., Loisel, S., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22603 · Cited by 220 · see citing works

Diagnostic value of labial minor salivary gland biopsy for Sjögren's syndrome: A systematic review

Guellec, D., Cornec, D., Jousse‐Joulin, S., Marhadour, T., Marcorelles, P., Pers, J., Saraux, A., & Devauchelle‐Pensec, V. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.08.001 · Cited by 183 · see citing works

Ectopic Germinal Centers Are Rare in Sjögren’s Syndrome Salivary Glands and Do Not Exclude Autoreactive B Cells

Pottier, L. L., Devauchelle‐Pensec, V., Fautrel, A., Daridon, C., Saraux, A., Youinou, P., & Pers, J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803588 · Cited by 164 · see citing works

Sjögren’s syndrome, the old and the new

Peri, Y., Agmon‐Levin, N., Theodor, E., & Shoenfeld, Y. (2012) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2012.01.012 · Cited by 137 · see citing works

T and B Lymphocytes in Peripheral Blood and Tissue Lesions in Sjögren's Syndrome

Talal, N., Sylvester, R. A., Daniels, T. E., Greenspan, J. S., & Williams, R. C. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107536 · Cited by 128 · see citing works

Identification of transitional type II B cells in the salivary glands of patients with Sjögren's syndrome

Daridon, C., Pers, J., Devauchelle‐Pensec, V., Martins-Carvalho, C., Hutin, P., Pennec, Y., Saraux, A., & Youinou, P. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21936 · Cited by 124 · see citing works

Efficacy of rituximab in primary Sjögren's syndrome with peripheral nervous system involvement: results from the AIR registry

MEKINIAN, A., Ravaud, P., Hatron, P., Larroche, C., Leone, J., Gombert, B., Hamidou, M. A., Cantagrel, A. G., Marcelli, C., Rist, S., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200086 · Cited by 123 · see citing works

Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab

Meiners, P. M., Arends, S., Brouwer, E., Spijkervet, F. K. L., Vissink, A., & Bootsma, H. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200460 · Cited by 113 · see citing works

Primary Sjögren's syndrome: a subjective description of the disease.

Bjerrum, K. B., & Prause, J. U. (1990) · PubMed · Cited by 77 · see citing works

Gene expression profile in the salivary glands of primary Sjögren's syndrome patients before and after treatment with rituximab

Devauchelle‐Pensec, V., Cagnard, N., Pers, J., Youinou, P., Saraux, A., & Chiocchia, G. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27509 · Cited by 55 · see citing works

Standardization of the Lysozyme Test for a Commercially Available Medium

Bijsterveld, O. P. V. (1974) · Archives of Ophthalmology · doi:10.1001/archopht.1974.03900060446002 · Cited by 47 · see citing works

Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies

Ho (2001) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200110)44:10 · Cited by 3 · see citing works

Primary Sjögren’s Syndrome

Xavier Mariette, A., & Criswell, L. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmcp1702514 · Cited by 977 · see citing works

Sjögren syndrome

Brito‐Zerón, P., Baldini, C., Bootsma, H., Bowman, S., Jonsson, R., Xavier Mariette, A., Sivils, K. L. M., Theander, E., Tzioufas, A. G., & Ramos‐Casals, M. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.47 · Cited by 875 · see citing works

EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies

Ramos-Casals, M., Brito-Zerón, P., Bombardieri, S., Bootsma, H., De Vita, S., Dörner, T., Fisher, B. A., Gottenberg, J.-E., Hernandez-Molina, G., Kocher, A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216114 · Cited by 732 · see citing works

The Catastrophic Antiphospholipid Syndrome

Rodríguez‐Pintó, I., Espinosa, G., & Cervera, R. (2014) · Rare diseases of the immune system · doi:10.1007/978-3-319-11044-8_20 · Cited by 493 · see citing works

BAFF and BAFF-Receptor in B Cell Selection and Survival

Smulski, C. R., & Eibel, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02285 · Cited by 372 · see citing works

B cells in the pathogenesis of primary Sjögren syndrome

Nocturne, G., & Xavier Mariette, A. (2018) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2018.1 · Cited by 356 · see citing works

Pulmonary manifestations of Sjögren's syndrome

Flament, T., Bigot, A., Chaigne, B., Henique, H., Diot, É., & Marchand-Adam, S. (2016) · European Respiratory Review · doi:10.1183/16000617.0011-2016 · Cited by 331 · see citing works

Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)

Séror, R., Bootsma, H., Saraux, A., Bowman, S., Theander, E., Brun, J. G., Baron, G., Guern, V. L., Devauchelle‐Pensec, V., Ramos‐Casals, M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206008 · Cited by 320 · see citing works

Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome

Gottenberg, J., Ravaud, P., Puéchal, X., Guern, V. L., Sibilia, J., Goëb, V., Larroche, C., Dubost, J., Rist, S., Saraux, A., et al. (2014) · JAMA · doi:10.1001/jama.2014.7682 · Cited by 311 · see citing works

Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis

Verstappen, G. M. P. J., Pringle, S. A., Bootsma, H., & Kroese, F. G. M. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00605-2 · Cited by 313 · see citing works

Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome

Bowman, S. J., Everett, C. C., O'Dwyer, J. L., Emery, P., Pitzalis, C., Ng, W., Pease, C. T., Price, E. J., Sutcliffe, N., Gendi, N. S. T., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40093 · Cited by 276 · see citing works

Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders

Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 265 · see citing works

Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy

Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222 · see citing works

Update on the pathophysiology and treatment of primary Sjögren syndrome

Baldini, C., Fulvio, G., Rocca, G. L., & Ferro, F. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01135-3 · Cited by 217 · see citing works

The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review

Cervera, R., Rodríguez‐Pintó, I., & Espinosa, G. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.05.007 · Cited by 219 · see citing works

Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

Bowman, S., Fox, R. I., Dörner, T., Xavier Mariette, A., Papas, A., Grader‐Beck, T., Fisher, B. A., Barcelos, F., Vita, S. D., Schulze‐Koops, H., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02251-0 · Cited by 212 · see citing works

Physiology, Pathology and Regeneration of Salivary Glands

Porcheri, C., & Mitsiadis, T. A. (2019) · Cells · doi:10.3390/cells8090976 · Cited by 201 · see citing works

Salivary gland function, development, and regeneration

Chibly, A. M., Aure, M. H., Patel, V. N., & Hoffman, M. P. (2022) · Physiological Reviews · doi:10.1152/physrev.00015.2021 · Cited by 207 · see citing works

Reviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatment

Both, T., Dalm, V. A. S. H., van Hagen, P. M., & van Daele, P. L. A. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.17718 · Cited by 198 · see citing works

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Dörner, T., Posch, M. G., Li, Y., Pétricoul, O., Cabanski, M., Milojevic, J., Kamphausen, E., Valentin, M., Simonett, C., Mooney, L., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214720 · Cited by 193 · see citing works

Treatment of primary Sjögren syndrome

Saraux, A., Pers, J., & Devauchelle‐Pensec, V. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2016.100 · Cited by 188 · see citing works

Current State of Knowledge on Primary Sjögren’s Syndrome, an Autoimmune Exocrinopathy

Parisis, D., Chivasso, C., Perret, J., Soyfoo, M. S., & Delporte, C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072299 · Cited by 183 · see citing works

A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome

Soret, P., Dantec, C. L., Desvaux, E., Foulquier, N., Chassagnol, B., Hubert, S., Jamin, C., Barturen, G., Desachy, G., Devauchelle‐Pensec, V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23472-7 · Cited by 173 · see citing works

Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies

Thorlacius, G. E., Björk, A., & Wahren‐Herlenius, M. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00932-6 · Cited by 164 · see citing works

New Treatment Guidelines for Sjögren's Disease

Vivino, F. B., Carsons, S. E., Foulks, G. N., Daniels, T. E., Parke, A. L., Brennan, M. T., Forstot, S. L., Scofield, R. H., & Hammitt, K. M. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.03.010 · Cited by 162 · see citing works

Current and future therapies for primary Sjögren syndrome

Séror, R., Nocturne, G., & Mariette, X. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00634-x · Cited by 162 · see citing works

Sjögren's syndrome: Old and new therapeutic targets

Mavragani, C. P., & Moutsopoulos, H. Μ. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102364 · Cited by 154 · see citing works

Is salivary gland ultrasonography a useful tool in Sjögren’s syndrome? A systematic review

Jousse‐Joulin, S., Milić, V., Jonsson, M. V., Plagou, A., Theander, E., Luciano, N., Pascale, R., Baldini, C., Bootsma, H., Vissink, A., et al. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev385 · Cited by 151 · see citing works

Treatment Guidelines for Rheumatologic Manifestations of Sjögren's Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain

Carsons, S. E., Vivino, F. B., Parke, A. L., Carteron, N. L., Sankar, V., Brasington, R., Brennan, M. T., Ehlers, W. H., Fox, R. I., Scofield, R. H., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22968 · Cited by 149 · see citing works

A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren’s syndrome

Xavier Mariette, A., Barone, F., Baldini, C., Bootsma, H., Clark, K. L., Vita, S. D., Gardner, D. H., Henderson, R. B., Herdman, M. J., Lerang, K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.163030 · Cited by 144 · see citing works

Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research

Davies, K., Dures, E. K., & Ng, W. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00692-1 · Cited by 143 · see citing works

Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial

Baer, A. N., Gottenberg, J., Clair, E. W. S., Sumida, T., Takeuchi, T., Séror, R., Foulks, G. N., Nys, M., Mukherjee, S., Wong, R. L., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218599 · Cited by 134 · see citing works

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?

Giacomelli, R., Afeltra, A., Alunno, A., Baldini, C., Bartoloni, E., Berardicurti, O., Carubbi, F., Cauli, A., Cervera, R., Ciccia, F., et al. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.012 · Cited by 133 · see citing works

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases

Yusof, M. Y. M., Vital, E. M. J., McElvenny, D. M., Hensor, E. M. A., Das, S., Dass, S., Rawstron, A. C., Buch, M. H., Emery, P., & Savic, S. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40937 · Cited by 118 · see citing works

Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis

Turk, M., Hayworth, J. L., Nevskaya, T., & Pope, J. E. (2020) · The Journal of Rheumatology · doi:10.3899/jrheum.190768 · Cited by 117 · see citing works

Brief Report: Ultrasonographic Assessment of Salivary Gland Response to Rituximab in Primary Sjögren's Syndrome

Jousse‐Joulin, S., Devauchelle‐Pensec, V., Cornec, D., Marhadour, T., Bressollette, L., Gestin, S., Pers, J., Nowak, E., & Saraux, A. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39088 · Cited by 112 · see citing works

Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy

Fisher, B. A., Everett, C., Rout, J., O'Dwyer, J. L., Emery, P., Pitzalis, C., Ng, W., Carr, A., Pease, C. T., Price, E., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212268 · Cited by 111 · see citing works

Treatment of Sjögren’s syndrome: current therapy and future directions

Fox, R. I., Fox, C. M., Gottenberg, J., & Dörner, T. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez142 · Cited by 109 · see citing works

Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial

Felten, R., Devauchelle‐Pensec, V., Séror, R., Duffau, P., Saadoun, D., HACHULLA, E., Hatron, P., Salliot, C., Perdriger, A., Morel, J., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218467 · Cited by 109 · see citing works

Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease

Corneth, O. B. J., Verstappen, G. M. P. J., Paulissen, S. M. J., de Bruijn, M. J. W., Rip, J., Lukkes, M. M., van Hamburg, J. P., Lubberts, E., Bootsma, H., Kroese, F. G. M., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40059 · Cited by 108 · see citing works

Renal involvement in primary Sjögren's syndrome.

Evans, R., Zdebik, A., Ciurtin, C., & Walsh, S. (2015) · Rheumatology · doi:10.1093/rheumatology/kev223 · Cited by 84 · see citing works

Anti-SSA/SSB-negative Sjögren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution

Quartuccio, L., Baldini, C., Bartoloni, E., Priori, R., Carubbi, F., Corazza, L., Alunno, A., Colafrancesco, S., Luciano, N., Giacomelli, R., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.07.002 · Cited by 108 · see citing works

Primary Sjögren's syndrome

Rischmueller, M., Tieu, J., & Lester, S. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.04.003 · Cited by 106 · see citing works

Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome

Séror, R., Baron, G., Camus, M., Cornec, D., Perrodeau, É., Bowman, S., Bombardieri, M., Bootsma, H., Gottenberg, J., Fisher, B. A., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-222054 · Cited by 106 · see citing works

The Multiple Roles of B Cells in the Pathogenesis of Sjögren’s Syndrome

Du, W., Han, M., Zhu, X., Xiao, F., Huang, E., Che, N., Tang, X., Zou, H., Jiang, Q., & Lu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.684999 · Cited by 105 · see citing works

Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment

Delli, K., Haacke, E. A., Kroese, F. G. M., Pollard, R., Ihrler, S., van der Vegt, B., Vissink, A., Bootsma, H., & Spijkervet, F. K. L. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208304 · Cited by 100 · see citing works

Current perspective on rituximab in rheumatic diseases

Schioppo, T., & Ingegnoli, F. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s139248 · Cited by 98 · see citing works

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome

Clair, E. W. S., Baer, A. N., Wei, C., Noaiseh, G., Parke, A. L., Coca, A., Utset, T. O., Genovese, M. C., Wallace, D. J., McNamara, J., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40513 · Cited by 96 · see citing works

Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity

Burbelo, P. D., Iadarola, M. J., Keller, J. M., & Warner, B. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.548469 · Cited by 95 · see citing works

Severe Health‐Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient‐Reported Outcomes: Data From a Large Therapeutic Trial

Cornec, D., Devauchelle‐Pensec, V., Xavier Mariette, A., Jousse‐Joulin, S., Berthelot, J., Perdriger, A., Puéchal, X., Guern, V. L., Sibilia, J., Gottenberg, J., et al. (2016) · Arthritis Care & Research · doi:10.1002/acr.22974 · Cited by 94 · see citing works

Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure

Arends, S., de Wolff, L., van Nimwegen, J. F., Verstappen, G. M. P. J., Vehof, J., Bombardieri, M., Bowman, S., Pontarini, E., Baer, A. N., Nys, M., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00122-3 · Cited by 92 · see citing works

B-Lymphocyte Depletion in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Fluge, Ø., Rekeland, I. G., Lien, K., Thürmer, H. L., Borchgrevink, P. C., Schäfer, C., Sørland, K., Aßmus, J., Ktoridou-Valen, I., Herder, I., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-1451 · Cited by 90 · see citing works

Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults

Baer, A. N., & Walitt, B. T. (2018) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2018.03.002 · Cited by 89 · see citing works

Mechanisms and New Strategies for Primary Sjögren's Syndrome

Mavragani, C. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-043015-123313 · Cited by 89 · see citing works

Innate immunity and interferons in the pathogenesis of Sjögren’s syndrome

Bodewes, I. L. A., Björk, A., Versnel, M. A., & Wahren‐Herlenius, M. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key360 · Cited by 88 · see citing works

Sjögren's syndrome

Thorne, I., & Sutcliffe, N. (2017) · British Journal of Hospital Medicine · doi:10.12968/hmed.2017.78.8.438 · Cited by 87 · see citing works

Renal Disease in Primary Sjögren’s Syndrome

Aiyegbusi, O., McGregor, L., McGeoch, L., Kipgen, D., Geddes, C., & Stevens, K. I. (2020) · Rheumatology and Therapy · doi:10.1007/s40744-020-00264-x · Cited by 85 · see citing works

Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren’s syndrome

Brito‐Zerón, P., Retamozo, S., Kostov, B., Baldini, C., Bootsma, H., Vita, S. D., Dörner, T., Gottenberg, J., Kruize, A. A., Mandl, T., et al. (2019) · RMD Open · doi:10.1136/rmdopen-2019-001064 · Cited by 83 · see citing works

Health-related quality of life and costs in Sjögren’s syndrome

Miyamoto, S. T., Valim, V., & Fisher, B. A. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key370 · Cited by 82 · see citing works

Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome

Cornec, D., Costa, S., Devauchelle‐Pensec, V., Jousse‐Joulin, S., Marcorelles, P., Berthelot, J., Chiche, L., HACHULLA, E., Hatron, P., Goëb, V., et al. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.11.002 · Cited by 81 · see citing works

Efficacy and safety of telitacicept in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled, phase 2 trial

Xu, D., Fang, J., Zhang, S., Huang, C., Huang, C., Li, Q., Li, X., Chen, M., Liu, X., Liu, Y., et al. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead265 · Cited by 81 · see citing works

Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study

Price, E., Bombardieri, M., Kivitz, A., Matzkies, F., Gurtovaya, O., Pechonkina, A., Jiang, W., Downie, B., Mathur, A. N., Mozaffarian, A., et al. (2022) · Lara D. Veeken · doi:10.1093/rheumatology/keac167 · Cited by 80 · see citing works

Advances in the understanding and treatment of systemic complications in Sjögren's syndrome

Brito‐Zerón, P., & Ramos‐Casals, M. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000096 · Cited by 79 · see citing works

A multicentre study of 95 biopsy-proven cases of renal disease in primary Sjögren’s syndrome

Jasiek, M., Karras, A., Guern, V. L., Krastinova, E., Mesbah, R., Faguer, S., Jourde‐Chiche, N., Fauchais, A. L., Chiche, L., Dernis, E., et al. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kew376 · Cited by 79 · see citing works

Cutaneous and Mucosal Manifestations of Sjögren’s Syndrome

Generali, E., Costanzo, A., Mainetti, C., & Selmi, C. F. (2017) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8639-y · Cited by 78 · see citing works

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

Giacomelli, R., Afeltra, A., Bartoloni, E., Berardicurti, O., Bombardieri, M., Bortoluzzi, A., Carubbi, F., Caso, F., Cervera, R., Ciccia, F., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102738 · Cited by 78 · see citing works

British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

Price, E., Benjamin, S., Bombardieri, M., Bowman, S., Carty, S., Ciurtin, C., Crampton, B., Dawson, A., Fisher, B. A., Giles, I., et al. (2024) · Lara D. Veeken · doi:10.1093/rheumatology/keae152 · Cited by 75 · see citing works

The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s Syndrome

Price, E., Rauz, S., Tappuni, A. R., Sutcliffe, N., Hackett, K. L., Barone, F., Granata, G., Ng, W., Fisher, B. A., Bombardieri, M., et al. (2017) · Lara D. Veeken · doi:10.1093/rheumatology/kex166 · Cited by 75 · see citing works

Reliability of histopathological salivary gland biopsy assessment in Sjogren's syndrome: a multicentre cohort study

Costa, S., Quintin‐Roué, I., Lesourd, A., Jousse‐Joulin, S., Berthelot, J., HACHULLA, E., Hatron, P., Goëb, V., Vittecoq, O., Pers, J., et al. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu453 · Cited by 69 · see citing works

Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren's syndrome

Milin, M., Cornec, D., Chastaing, M., Griner-Abraham, V., Berrouiguet, S., Nowak, E., Marhadour, T., Saraux, A., & Devauchelle‐Pensec, V. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2015.10.005 · Cited by 69 · see citing works

Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome

Gottenberg, J., Dörner, T., Bootsma, H., Devauchelle-Pensec, V., Bowman, S., Mariette, X., Bartz, H., Oortgiesen, M., Shock, A., Koetse, W., et al. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40425 · Cited by 54 · see citing works

The value of rituximab treatment in primary Sjögren's syndrome

Verstappen, G. M. P. J., van Nimwegen, J. F., Vissink, A., Kroese, F. G. M., & Bootsma, H. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.05.002 · Cited by 67 · see citing works

Interventions for dry mouth and hyposalivation in Sjögren’s syndrome: A systematic review and meta‐analysis

AlHamad, A. F., Lodi, G., Porter, S. R., Fedele, S., & Mercadante, V. (2018) · Oral Diseases · doi:10.1111/odi.12952 · Cited by 66 · see citing works

Update on the immunobiology of Sjögren's syndrome

Ambrosi, A., & Wahren‐Herlenius, M. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000195 · Cited by 65 · see citing works

Early diagnosis and treatment for Sjögren's syndrome: current challenges, redefined disease stages and future prospects

Wang, B., Chen, S., Zheng, Q., Li, Y., Zhang, X., Xuan, J., Liu, Y., & Shi, G. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102590 · Cited by 64 · see citing works

Rituximab Effectiveness and Safety for Treating Primary Sjögren’s Syndrome (pSS): Systematic Review and Meta-Analysis

Souza, F. B. D. V., Porfírio, G. J. M., Andriolo, B. N. G., de Albuquerque, J. V., & Trevisani, V. F. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150749 · Cited by 64 · see citing works

B Cell Depletion Therapy Normalizes Circulating Follicular Th Cells in Primary Sjögren Syndrome

Verstappen, G. M. P. J., Kroese, F. G. M., Meiners, P. M., Corneth, O. B. J., Huitema, M. G., Haacke, E. A., van der Vegt, B., Arends, S., Vissink, A., Bootsma, H., et al. (2016) · The Journal of Rheumatology · doi:10.3899/jrheum.160313 · Cited by 63 · see citing works

Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome

Maciel, G., Crowson, C. S., Matteson, E. L., & Cornec, D. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.020 · Cited by 63 · see citing works

Clinical practice guideline for Sjögren’s syndrome 2017

Sumida, T., Azuma, N., Moriyama, M., Takahashi, H., Asashima, H., Honda, F., Abe, S., Ono, Y., Hirota, T., Hirata, S., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2018.1438093 · Cited by 63 · see citing works

B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells

Bonasia, C. G., Abdulahad, W. H., Rutgers, A., Heeringa, P., & Bos, N. A. (2021) · Cells · doi:10.3390/cells10051190 · Cited by 60 · see citing works

Variability of Primary Sjögren's Syndrome Is Driven by Interferon‐α and Interferon‐α Blood Levels Are Associated With the Class II HLA–DQ Locus

Trutschel, D., Bost, P., Xavier Mariette, A., Bondet, V., Llibre, A., Posseme, C., Charbit, B., Thorball, C., Jonsson, R., Lessard, C. J., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42265 · Cited by 58 · see citing works

High-Grade Salivary-Gland Involvement, Assessed by Histology or Ultrasonography, Is Associated with a Poor Response to a Single Rituximab Course in Primary Sjögren’s Syndrome: Data from the TEARS Randomized Trial

Cornec, D., Jousse‐Joulin, S., Costa, S., Marhadour, T., Marcorelles, P., Berthelot, J., HACHULLA, E., Hatron, P., Goëb, V., Vittecoq, O., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162787 · Cited by 60 · see citing works

Labial Gland Mesenchymal Stem Cell Derived Exosomes-Mediated miRNA-125b Attenuates Experimental Sjogren’s Syndrome by Targeting PRDM1 and Suppressing Plasma Cells

Xing, Y., Li, B., He, J., & Hua, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.871096 · Cited by 62 · see citing works

Chronic Autoimmune Epithelitis in Sjögren’s Syndrome and Primary Biliary Cholangitis: A Comprehensive Review

Selmi, C. F., & Gershwin, M. E. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-017-0074-2 · Cited by 57 · see citing works

Biologic treatment in Sjogren's syndrome

Sada, P. R., Isenberg, D. A., & Ciurtin, C. (2014) · Lara D. Veeken · doi:10.1093/rheumatology/keu417 · Cited by 57 · see citing works

Innate Immunity and Biological Therapies for the Treatment of Sjögren’s Syndrome

Srivastava, A., & Makarenkova, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239172 · Cited by 44 · see citing works

Development of the Sjögren’s Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy

Cornec, D., Devauchelle‐Pensec, V., Xavier Mariette, A., Jousse‐Joulin, S., Berthelot, J., Perdriger, A., Puéchal, X., Guern, V. L., Sibilia, J., Gottenberg, J., et al. (2015) · Lara D. Veeken · doi:10.1093/rheumatology/kev114 · Cited by 56 · see citing works

Arthritis in primary Sjögren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study

Mirouse, A., Séror, R., Vicaut, É., Xavier Mariette, A., Dougados, M., Fauchais, A. L., Deroux, A., Dellal, A., Costedoat-Chalumeau, N., Denis, G., et al. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.06.015 · Cited by 54 · see citing works

Catastrophic antiphospholipid syndrome: The current management approach

Rodríguez‐Pintó, I., Espinosa, G., & Cervera, R. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.07.004 · Cited by 53 · see citing works

The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy

Hale, M. R., Rawlings, D. J., & Jackson, S. W. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.10.008 · Cited by 53 · see citing works

B cell-activating factor and its targeted therapy in autoimmune diseases

Zhang, Y., Tian, J., Xiao, F., Zheng, L., Zhu, X., Wu, L., Zhao, C., Wang, S., Rui, K., Zou, H., et al. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.11.004 · Cited by 52 · see citing works

Sjögren’s syndrome

André, F., & Böckle, B. C. (2022) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14823 · Cited by 52 · see citing works

Recent advances in primary Sjogren's syndrome

Holdgate, N., & Clair, E. W. S. (2016) · F1000Research · doi:10.12688/f1000research.8352.1 · Cited by 52 · see citing works

Current views on the pathogenesis of Sjögren's syndrome

Pontarini, E., Lucchesi, D., & Bombardieri, M. (2017) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000473 · Cited by 52 · see citing works

Identification of definitive serum biomarkers associated with disease activity in primary Sjögren’s syndrome

Nishikawa, A., Suzuki, K., Kassai, Y., Gotou, Y., Takiguchi, M., Miyazaki, T., Yoshimoto, K., Yasuoka, H., Yamaoka, K., Morita, R., et al. (2016) · Arthritis Research & Therapy · doi:10.1186/s13075-016-1006-1 · Cited by 51 · see citing works

Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin

MacIsaac, J., Siddiqui, R., Jamula, E., Li, N., Baker, S. K., Webert, K. E., Evanovitch, D., Heddle, N. M., & Arnold, D. M. (2018) · Transfusion · doi:10.1111/trf.14841 · Cited by 51 · see citing works

Immunotherapy Prospects for Painful Small-fiber Sensory Neuropathies and Ganglionopathies

Oaklander, A. L. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0395-1 · Cited by 50 · see citing works

Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren’s syndrome: evidence- and practice-based guidance

Marinho, A., Alves, J. D., Fortuna, J., Faria, R., Almeida, I., Alves, G., Correia, J. A., Campar, A., Brandão, M., Crespo, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1117699 · Cited by 49 · see citing works

Concurrent remission of lymphoma and Sjögren’s disease following anti-CD19 chimeric antigen receptor-T cell therapy for diffuse large B-cell lymphoma: a case report

Sheng, L., Zhang, Y., Song, Q., Jiang, X., Cao, W., Li, L., Yi, H., Weng, X., Chen, S., Wang, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298815 · Cited by 49 · see citing works

Rituximab in systemic autoimmune rheumatic diseases: indications and practical use

Berghen, N., Vulsteke, J., Westhovens, R., Lenaerts, J., & Langhe, E. D. (2018) · Acta Clinica Belgica · doi:10.1080/17843286.2018.1521904 · Cited by 49 · see citing works

Treatment of Primary Sjogren Syndrome With Rituximab

Trial, A. R., Nowak, E., & Saraux, A. (2015)

OP0065 Tolerance and efficacy of rituximab in primary sjogren syndrome (TEARS): Results of a randomized controlled trial

Devauchelle‐Pensec, V., Xavier Mariette, A., Jousse‐Joulin, S., Berthelot, J. M., Perdriger, A., HACHULLA, E., Puéchal, X., Guern, V. L., Sibilia, J., Gottenberg, J., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-eular.1748 · Cited by 12 · see citing works

Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

Gottenberg, J., Cinquetti, G., Larroche, C., Combe, B. G., HACHULLA, E., Meyer, O., Pertuiset, É., Kaplanski, G., Chiche, L., Berthelot, J., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-202293 · Cited by 226 · see citing works

Rituximab Effectiveness and Safety for Treating Primary Sjögren's Syndrome (pSS): Systematic Review and Meta-Analysis

Souza, F. B. D. V. [. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

FRI0325 Rituximab in primary sjÖgren's syndrome: a systematic review on its efficacy

Greco, M., Montes, J. D. P., del Campo, P. D., Castro, M. F., Francisco, F., & Andreu, J. L. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-eular.6914